Through his research at Caltech, a local high school student revealed 1.5 million previously unknown objects in space, broadened the potential of a ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and ...

Truist lowered the firm’s price target on Regeneron (REGN) to $975 from $1,004 and keeps a Buy rating on the shares. The firm notes Regeneron has pulled back over the last few quarters on Eylea ...

“Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories. Our innovative ...

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity. Valued at more than $3bn, the partnership is set to ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition, with Eylea HD showing strong performance and new innovations like a pre-filled syringe on the horizon. Dupixent ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

This edition of Org Chart has news on a number of centers around campus, as well as a new endowed chair, a key financial position and more. Geophysicist Amanda Thomas has been named the inaugural ...

April 22 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN – Research Report) and Surgery ...